Parexel Podcasts

The Parexel Podcast | Episode 16: COVID-19 Vaccines and Kids: The Research and Vaccine Explained

11.18.21 - In the United States, the FDA and CDC recently granted emergency use authorization (EUA) for Pfizer’s COVID-19 vaccine for 5–11-year-olds, making it the first COVID-19 vaccine available for younger children and arriving nearly one year after Pfizer’s COVID-19 vaccine received EUA for adults. If the adult vaccine was authorized for this long, why did it take so long to make one available for younger children?


The Parexel Podcast | Episode 15: Pandemic preparedness: Investing in the future of infectious disease vaccine development

02.08.21 - Viral infections continue to emerge and represent a serious threat to global public health, from SARS to H1N1 influenza to MERS. Yet none has caused the level of global devastation levied by the coronavirus. In fact, the long-term complications of COVID-19 on our healthcare system are just beginning to come into focus. Managing these complications will increase the demand for healthcare resources in the years to come and will elevate the need for novel therapies to manage them. This episode features Sy Pretorius, Parexel’s President, Clinical Development & Chief Medical Officer; Paul Bridges, Senior Vice President, Regulatory and Access at Parexel; and Ruggero Rossi, Vice President, Health Advances on how biopharmaceutical companies are preparing for COVID-19-related complications, the development of novel treatments to manage them, and future investments in vaccine development for infectious diseases so that we are better prepared for future pandemics.


The Parexel Podcast | Episode 14: Why Parents and Children Join Research Studies: CISCRP’s 2020 Pediatric Perceptions & Insights Survey Reveals Critical Insights

12.08.20 - Pediatric participation in clinical trials is essential to understanding how drugs perform in children, whose side effects and responses to medications are often very different from adults. Yet the vast majority of medications are only evaluated in adults, and pediatric participation in clinical trials remains exceedingly low worldwide. In this podcast, experts discuss critical insights gleaned from a survey of 500 parents and children about their perceptions and experiences of clinical research.


The Parexel Podcast | Episode 13: The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

07.30.20 - Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief Commercial and Strategy Officer, talks with Paul Bridges, Worldwide Head of Regulatory and Access, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism.


The Parexel Podcast | Episode 12: ASCO20 Debrief: The latest in cell and gene therapy

06.05.20 - In this podcast, clinical industry experts discuss the progress made in cell and gene therapy as presented at ASCO and how the industry can continue to move these developments forward today and in the future.


We are always available for a conversation.